NCT05978284View on ClinicalTrials.gov

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 27, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Small Cell Lung CancerNeuroendocrine Carcinoma
Interventions
BIOLOGICAL

ZG006

ZG006 will be administered as an intravenous (IV) infusion.

Trial Locations (1)

Unknown

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY